Merck to Present New Data on Investigational Chronic Hepatitis C Treatment Elbasvir/Grazoprevir at The Liver Meeting® 2015, Including Phase 3 Results in Selected Difficult-to-Treat Populations
Dateline City:
KENILWORTH, N.J.
New Data Will Also be Presented from Phase 2a C-CREST Trials of Merck’s Investigational Triple-Combination Chronic Hepatitis C Therapies
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that new data from clinical trials of its
investigational treatment portfolio for chronic hepatitis C virus (HCV)
are scheduled to be presented at The
Liver Meeting® 2015 (the 66th
annual scientific congress of the American Association for the Study of
Liver Diseases) in San Francisco, from Nov. 13-17, 2015. Merck’s
late-stage investigational portfolio includes elbasvir/grazoprevir1,
MK-36822 and MK-84083.
Language:
English
Contact:
MerckMedia:Doris Li, 908-246-5701Sarra Herzog, 908-740-1871orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Hepatitis C Newsroom Research and Development News Corporate News Latest News Source Type: news
More News: Clinical Trials | Hepatitis | Hepatitis C | Liver | Liver Disease | Merck | Pharmaceuticals | Politics | Study | Urology & Nephrology